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The interaction of the acetylcholine receptor (AChR) binding site domain with specific antibodies and with a-bungarotoxin (a-BTX) has been 
compared. The cloned and expressed ligand binding domain of the mouse AChR a-subunit binds a-BTX, whereas the mongoose-expressed domain 
is not recognized by a-BTX. On the other hand, both the mouse and mongoose domains bind to the site-specific monoclonal antibody 5.5. These 
results demonstrate that the structural requirements for binding of a-BTX and mcAb 5.5, both of which interact with the AChR binding site, are 
distinct from each other. 
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1. INTRODUCTION 
The muscle nicotinic acetylcholine receptor (AChR) 
is a well characterized ligand-gated ion channel ocated 
in the postsynaptic folds of the neuromuscular junction. 
It is an integral membrane glycoprotein which forms an 
oligomeric complex composed of four subunits present 
in a molar stochiometry of a&6 with an overall molec- 
ular weight of 250,000 Da [1,2]. Among these four sub- 
units, the cholinergic binding site was shown to be lo- 
cated in a portion of the extacellular domain of the 
a-subunit, within a region containing the tandem cys- 
teines at residues 192 and 193 [3-71. Nevertheless, it 
should be noted that recent studies using specific affin- 
ity-labeling ligands suggest the involvement of addi- 
tional amino acid residues from other domains of the 
a-subunit and possibly from other subunits in ligand 
binding [8]. 
from animals such as certain snakes and the mongoose, 
which are known to be resistant o neurotoxins [10,13]. 
In order to understand the structural basis which con- 
fers this pharmacological specificity, we have cloned a 
fragment from the AChR a-subunit extracellular do- 
main, comprising residues 122 to 205 from three differ- 
ent snake species [12,13], and from the mongoose [13]. 
We demonstrated that several major substitutions occur 
at the putative binding site of the snakes and mongoose, 
in the vicinity of cysteines 192 and 193. Expression of 
the cloned AChR fragments in bacteria and analysis of 
a-BTX binding on Western blots suggest that these sub- 
stitutions may be sufficient to account form the special 
pharmacology of these receptors [13]. 
As the natural ligand of the AChR, acetylcholine, has 
a low affinity to its receptor, the snake polypeptide 
neurotoxin, ol-bungarotoxin (ol-BTX), which has high 
affinity to the receptor and can be easily radiolabeled, 
has been particularly instrumental in the localization of 
the ligand binding site. However, not all the nicotinic 
AChRs bind snake neurotoxins [9,10] indicating that 
the binding sites for a a-BTX and for acetylcholine may 
be overlapping but not identical. 
In an attempt to analyze this question, we have been 
studying the ligand binding region of muscle AChRs 
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In this report we have employed immunological rea- 
gents for further analysis and characterization of the 
ligand binding site of the AChR. Both polyclonal anti- 
bodies directed against distinct domains of the AChR 
[5,14] as well as the monoclonal antibody 5.5.G.12 
(mcAb5.5) [15] were used. Monoclonal antibody 5.5 
was developed in our laboratory as a highly specific 
reagent directd against the AChR binding site and was 
shown to compete with cholinergic agonists and antag- 
onists, including a-neurotoxins, in receptor binding, 
and to directly act as a cholinergic antagonist in block- 
ing acetylcholine-induced sodium transport and modi- 
fying ionic channel properties [15-l 71. We describe here 
the interaction of cloned and expressed ligand-binding 
domains from mouse and mongoose AChR, which vary 
in their response to a-BTX, with various antipeptide 
antibodies and with mcAb5.5. We demonstrate that the 
loss of cr-BTX binding is not accompanied by a similar 
loss of specific antibody binding. Our results support 
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the notion that, despite the physical vicinity or overlap- 
ping of their binding sites, there may be distinct require- 
ments for the binding of acetylcholine and a-BTX. 
2. MATERIALS AND METHODS 
2.1. Preparation of antibodies 
The recombinant a-subunit domains, coding for amino acids 122 to 
205 from mouse and mongoose AChR, were subcloned into the ex- 
pression vector PET-SC and expressed as described [13]. Polyclonal 
antibodies against these expressed fragments were raised in rabbits 
following injection of gel-purified bacterial expressed proteins as de- 
scribed [13]. Anti-p126143 and ~143-158 antibodies are directed 
against synthetic peptides corresponding to residues 126143 and 143- 
158 of the Torpedo AChR a-subunit, respectively [5,14]. McAb5.5 is
directed against he acetylcholine binding site of the AChR [15], and 
mcAb5.14 is directed against a highly immunogenic determinant lo- 
cated at a 14 kDa C-terminal fragment of the AChR a-subunit [18]. 
Ascitic fluids containing these monoclonal antibodies were employed 
]151. 
2.2. Western blot overlays 
Bacterially expressed cc-subunit domains from mongoose and 
mouse AChR or partially purified Torpedo AChR were resolved by 
SDS-PAGE, and blotted onto nitrocellulose paper (Schleicher and 
Schuell). The blots were overlayed with polyclonal or monoclonal 
antibodies as described [5] and further probed with either iodinated 
protein A (for antipeptide antibodies) or iodinated goat-anti mouse 
IgG antibody (for monoclonal antibodies), or overlayed with ‘Q,- 
BTX [6]. 
2.3. In vitro translation and immunoprecipitation 
The cloned a-subunit domains were subcloned into pBluescript or 
pSP65 and RNA was transcribed from linearized vectors using T3 or 
SP6 RNA plymerases, respectively. In-vitro translation was per- 
formed in a rabbit reticulocyte lysates (Promega). Proteins were la- 
beled throughout ranslation with [“Slmethionine (Amersham). Prior 
to immunoprecipitation with polyclonal or monoclonal antibodies, 
the lysate was pre-cleared with sepharoseconjugated protein A or 
goat anti-mouse IgG, respectively. Immunoprocipitation of lysate 
proteins was performed as described [19]. The precipitated proteins 
were eluted from the beads, separated by SDS-PAGE on 15% gels, and 
visualized by fluorography. 
3. RESULTS 
The cloned &subunit domains from mouse and mon- 
goose AChR share 95% homology, with major substitu- 
tions in the vicinity of the putative ligand binding site. 
These domains are 82% homologous to the respective 
domain of the Torpedo AChR ([13]; Fig. 1, upper 
panel). We tested whether the cloned and expressed 
mouse and mongoose proteins can cross-react with var- 
ious antibodies raised against components of the Tor- 
pedo AChR. To that end, lysates from bacteria express- 
ing the cloned mouse and mongoose domains, as well 
as purified Torpedo AChR, were resolved in 15% 
acrylamide gels and blotted onto nitrocellulose. Identi- 
cal blots were then overlayed with several polyclonal 
antibodies or with a-BTX, using Torpedo AChR as a 
positive control. As demonstrated in Fig. 1 (lower 
panel), polyclonal antibodies against the entire AChR 
(Fig. 1, lower panel, b), anti-p128143 and ~143-156 
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Fig. 1. Sequence and immunological profile of bacterially expressed 
AChR domains. (Upper panel) Comparison of the primary amino 
acid sequence of the mongoose, mouse and Torpedo AChR residues 
122-205. The amino acids sequences are deduced from the cDNA 
sequence in the EMBL database and [13]. (Lower panel) Analysis of 
the bacterially expressed AChR domains with polyclonal antibodies. 
The mouse and mongoose domains, and purified Torpedo AChR, were 
resolved on 15% SDS-PAGE as described [13]. Identical samples were 
stained with Commassie brilliant blue (a) or transferred to nitrocellu- 
lose paper and interacted with polyclonal antibodies (be) or iodinated 
a-BTX (f). Immunoblots were further probed with ioidinated protein 
A. Lanes 1, molecular weight markers; 2 and 3, lysates from bacteria 
transfected with PET-8c containing the mouse or the mongoose 122- 
205 domain, respectively; 4, lysate from bacteria transfected with 
PET-8C; 5, Torpedo AChR. a, Coomassie brilliant blue staining; b, 
immunoblot with anti-Torpedo AChR antibodies; c and d, im- 
munoblot with anti-p128-143 or anti-p143-158 antibodies, respec- 
tively; e, immunoblot with antibodies directed against the bacterially 
expressed mongoose domain; and f, overlay of a similar blot with 
[‘251]a-BTX. bf present only the 8 kDa region in lanes 24, and the 
a-subunit (40 kDa) region in lanes 5. 
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Fig. 2. Immunological profile of in vitro expressed AChR domains. 
Cell free expression was performed in rabbit reticulocytes as described 
in section 2. Lysates expressing an irrelevant control mRNA (panel 
1), the entire mouse a-subunit (panel 2) the mouse domain coding for 
residues 122-205 (panel 3) and the mongoose domain coding for 
residues 122-205 (panel 4) were immunoprecipitated with the follow- 
ing polyclonal and monoclonal antibodies: anti-p1433158 (lanes a). 
mcAb5.5 (lanes b) and mcAb5.14 (lanes c). The immunoprecipitated 
proteins were resolved by 15% SDS-PAGE, and visualized by fluoro- 
graphy. The difference in band intensity results from the expression 
of a higher amount of labeled mouse domain in the initial in vitro 
translation reaction (data not shown), or probably due to the existence 
of an additional methionine m the mouse sequence (Fig. 1, upper 
panel). 
(Fig. 1, lower panel, c and d, respectively) were able to 
recognize an 8 kDa protein in bacteria that express the 
a-subunit domains. As demonstrated by Coomassie 
brilliant blue staining, this 8 kDa protein constitutes the 
major component of the total proteins expressed in plas- 
mid-harboring bacteria (Fig. 1, lower panel, a). The 
Torpedo AChR interacted with antibodies raised 
against gel-purified, expressed domain from the mon- 
goose a-subunit (Fig. 1, lower panel, e), as well as with 
antibodies raised against a similar domain from the 
expressed mouse domain (data not shown). On the 
other hand, the expressed domains retained their unique 
pharmacological properties on the Western blot. 
Namely, as reported earlier [13], the mouse fragment 
and the entire Torpedo u-subunit interacted with iodi- 
nated a-BTX while the mongoose fragment was not 
recognized by the toxin (Fig. 1, lower panel, f). 
As the bacterially expressed proteins are not soluble, 
we used cell-free expression in a eukaryotic system to 
determine whether the same immunological profile 
would be manifested also with soluble fragments. The 
mouse and mongoose fragments, as well as the entire 
mouse AChR subunit, were in vitro transcribed and 
translated using rabbit reticulocyte lysates. Under these 
conditions, the expressed domains are soluble and can 
therefore be analyzed by immunoprecipitation. As dem- 
onstrated in Fig. 2, panels a, the in vitro expressed 
mouse and mongoose fragments can interact with anti- 
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peptide antibodies against the Torpedo receptor domain 
143-158, as was demonstrated for the bacterially ex- 
pressed fragments (Fig. 1). The in vitro expressed pro- 
teins could also be precipitated with anti-Torpedo 
AChR antibodies and with antibodies elicited against 
the bacterially expressed domains (data not shown). 
Thus, soluble receptor domains expressed in a eukar- 
yotic system show the same cross-reactivity with various 
antibodies demonstrated by the denatured, immobi- 
lized, bacterially expressed receptor fragments. 
Monoclonal antibodies were instrumental in the 
study of the structure-function relations of various do- 
mains within the AChR, such as the ligand binding site 
and the major immunogenic regions involved in the 
pathology of Myasthaniu gravis [15,18,20]. These rea- 
gents are directed against a single immunogenic deter- 
minant, and could be used to probe into the conforma- 
tion of specific domains within the AChR. Monoclonal 
antibody 5.5 is especially interesting in this respect as 
this reagent is directed against the ligand binding site of 
the AChR in a conformation-dependent manner [15]. 
Thus it was interesting to determine whether this anti- 
body would interact with the cloned a-subunit domains, 
expressed both in vitro and in bacteria. As a control we 
used mcAb5.14. a monoclonal antibody directed 
against a highly immunogenic domain in the cytoplas- 
mic region of the a-subunit [18], which is not present in 
our cloned fragments. 
As demonstrated in Figs. 2 and 3, the a-subunit do- 
mains were recognized by mcAb5.5 when expressed in 
a cell free system or in bacteria. McAb5.5 immunopre- 
cipitated the in vitro expressed mouse and mongoose 
domains (Fig. 2, lanes b) as well as the entire a-subunit, 
while mcAb5.14 precipitated only the entire expressed 
mouse a-subunit (Fig. 2, lanes c). Similarly, bacterially 
expressed a-subunit domains immobilized on Western 
blots were identified by mcAb5.5 (Fig. 3, panel b) but 
not with mcAb5.14 (Fig. 3, panel c). Both antibodies 
reacted with Torpedo AChR a-subunit. (The bands ob- 
served at molecular weight higher than the a-subunit, 
probably represent dimers of a-subunit or heterdimers 
with the a-subunit.) These experiments demonstrate 
that the immunological behavior of the mouse and 
mongoose expresed domains is similar in both expres- 
sion systems. 
4. DISCUSSION 
Our results demonstrate that two reagents, both of 
which are specifically directed against the AChR bind- 
ing site, show different sequence specificity. a-BTX is 
widely used as an affinity ligand for muscle AChR a- 
subunit, while not recognizing other types of a-subunits 
such as certain subtypes present in the central nervous 
system [9,21]. In addition, a-BTX does not interact with 
the AChR a-subunit from various organisms that are 
resistant to snake toxins, such as certain snakes and the 
Volume 3 18, number 3 FEBS LETTERS March 1993 
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Fig. 3. Interaction of bacterially expressed AChR domains with monoclonal antibodies. Lysates from bacteria expressing the mouse and mongoose 
AChR domains, as well as Torpedo electric organ AChR, were resolved by SDS-PAGE and immobilized on nitrocellulose as described in the legend 
to Fig. 1, lower panel. Idential gels were stained with Coomassie brilliant blue (panel a), or blotted and overlayed with mcAb5.5 (panel b) or 
mcAb5.14 (panel c). Immunoblots were further probed with iodinated goat anti-mouse IgG antibodies. Lanes 1, molecular weight markers; 2, 
Torpedo AChR; 3, expressed mouse domain; 4, expressed mongoose domain. The bands observed at molecular weight higher than the a-subunit, 
probably represent dimers of a-subunit or heterodomers with the a-subunit. 
mongoose [ 12,131. Our study using the bacterially ex- 
pressed proteins demonstrates that the specificity of this 
interaction is directly determined by the primary amino 
acid sequence (Fig. 1). This conclusion is supported by 
the findings of other groups, using synthetic peptides 
[22] or fusion proteins [23]. 
Monoclonal antibody mcAb5.5 is directed against the 
cholinergic binding site, as could be deduced by the 
following criteria: competition with a-BTX for binding 
the entire Torpedo AChR [ 151 as well as for binding to 
proteolytic fragments harboring the putative choliner- 
gic binding site [7,18]; inhibition of antibody binding to 
the AChR by nicotinic agonists, [15]; and antibody- 
mediated competitive inhibition of ligand-induced ion 
channels in cells expressing the muscle nicotinic AChR 
[16,17]. This antibody is conformation-specific, as it 
does not recognize denatured AChR [15]. Our results 
demonstrate that this antibody can recognize the cloned 
a-subunit domains, expressed both in a soluble form in 
vitro and in an insoluble form in bacteria. The interac- 
tion of mcAb5.5 with the immobilized proteins, that 
were subjected to electrophoresis in denaturing condi- 
tions, suggests that these domains can undergo partial 
renaturation upon transfer, which is sufficient to restore 
the structure of the antibody binding site. 
The different interaction of ol-BTX and mcAb5.5 with 
the mouse and mongoose domains suggests that these 
two reagents recognize different moieties within the li- 
gand binding site. The cholinergic binding site is de- 
signed to be recognized by acetylcholine, a small mole- 
cule, and it is plausible to assume that selective pressure 
against toxing binding would design a sequence that is 
able to recognize acetylcholine but not a-BTX. Our 
results demonstrate that the amino acid substitutions 
involved in conferring toxin resistance did not abolish 
the interaction of the a-subunit domain with mcAb5.5. 
Thus, mcAb5.5 is directed against an overlapping, but 
not identical, structure within the cholinergic binding 
site. These results suggest that the specific requirements 
for binding of various reagents such as a-BTX, 
mcAb5.5, and acetylcholine, all of which interact with 
the AChR binding site, are distinct form each other. 
Determination of the specific residues required for 
mcAb5.5 recognition, and comparison with the known 
specificity of acetylcholine binding site, could provide 
further insight into this question. 
An obvious advantage of a cholinergic reagent that 
is not limited by the receptor specificity for ol-BTX, is 
the ability to use such a reagent in the study of a sub- 
group of nicotinic AChRs which do not bind a-BTX. 
Even in animals that harbor a-BTX-sensitive muscle 
AChRs, the AChRs from other tissues, including the 
267 
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central nervous system, differ in their capability to bind 
a-BTX. As demonstrated in this paper, mcAb5.5 is a 
reagent hat can bind to the ligand binding site also of 
AChRs that do not recognize a-BTX. Thus, mcAb5.5 
may be used as an affinity reagent in the purification, 
localization and characterization of ligand binding sites 
in such receptors. 
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